CHINA PHARMA HOLDINGS, INC. Interest Expense on Debt
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Interest Expense on Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2026-08-14
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for the quarter ending 2026-06-30 was -$6.48K.
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for the quarter ending 2026-03-31 was $6.48K, a 34.71% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for the quarter ending 2025-12-31 was $6.45K.
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for the quarter ending 2025-09-30 was $23.40K, a 128.89% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for fiscal 2025 was $32.24K.
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for fiscal 2023 was $15.76K, a 83.21% decline from fiscal 2022.
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for fiscal 2022 was $93.85K, a 63.23% decline from fiscal 2021.
- CHINA PHARMA HOLDINGS, INC. interest expense, debt for fiscal 2021 was $255.22K, a 121.57% increase from fiscal 2020.
USD
| Period end | Interest Expense, Debt 3 month | Interest Expense, Debt 6 month | Interest Expense, Debt 6 month as first filed | Interest Expense, Debt 9 month | Interest Expense, Debt 9 month as first filed | Interest Expense, Debt 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $6.45K derived: sum of 3 quarters · filed 2026-08-14 | $29.84K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $6.48K 10-Q · filed 2026-05-15 | $12.92K derived: sum of 2 quarters · filed 2026-05-15 | $36.32K derived: sum of 3 quarters · filed 2026-05-15 | $28.79K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $6.45K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $29.84K derived: sum of 2 quarters · filed 2026-04-01 | $22.32K derived: sum of 3 quarters · filed 2026-08-14 | $32.24K 10-K · filed 2026-04-01 | ||
| 2025-09-30 | $23.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.87K derived: sum of 2 quarters · filed 2026-08-14 | $25.79K 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$7.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.39K 10-Q · filed 2026-08-14 | $19.61K 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $9.92K 10-Q · filed 2026-05-15 | |||||
| 2024-09-30 | $10.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $29.52K 10-Q · filed 2025-11-12 | $540.00K 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $19.30K 10-Q · filed 2025-08-14 | |||||
| 2023-12-31 | -$21.81K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$9.41K derived: sum of 2 quarters · filed 2024-04-01 | -$4.10K derived: sum of 3 quarters · filed 2024-04-01 | $15.76K 10-K · filed 2024-04-01 | ||
| 2023-09-30 | $12.40K 10-Q · filed 2023-11-13 | $17.71K derived: sum of 2 quarters · filed 2023-11-13 | $37.57K 10-Q · filed 2023-11-13 | $94.14K derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2023-06-30 | $5.31K 10-Q · filed 2023-08-14 | $10.57K 10-Q · filed 2023-08-14 | $81.74K derived: sum of 3 quarters · filed 2024-04-01 | $95.14K derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2023-03-31 | $12.60K 10-Q · filed 2023-05-12 | $76.43K derived: sum of 2 quarters · filed 2024-04-01 | $89.83K derived: sum of 3 quarters · filed 2024-04-01 | $95.50K derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2022-12-31 | $63.83K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $77.23K derived: sum of 2 quarters · filed 2024-04-01 | $82.91K derived: sum of 3 quarters · filed 2024-04-01 | $93.85K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $13.40K 10-Q · filed 2023-11-13 | $19.08K derived: sum of 2 quarters · filed 2023-11-13 | $30.02K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $5.68K 10-Q · filed 2023-08-14 | $11.35K 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | $15.16K 10-Q · filed 2023-05-12 | |||||
| 2021-12-31 | $255.22K 10-K · filed 2023-03-30 | |||||
| 2020-12-31 | $115.19K 10-K · filed 2022-03-30 |
CNY
| Period end | Interest Expense, Debt 9 month |
|---|---|
| 2024-09-30 | 3.80M CNY 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |